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Hypertension, a major contributor to cardiovascular disease (CVD) including heart disease 
and stroke, is one of the leading contributors of global burden of disease and a growing 
public health problem worldwide.1 In the U.S., about 75.2 million adults (one in every three) 
had hypertension during 2013–2014.2 In 2014, hypertension was listed as a primary or 
contributing cause of 427,631 American deaths, and heart disease and stroke were the first-
and fifth-leading causes of death respectively.3 Economically, hypertension cost the nation 
about $51.2 billion per year, and total CVD cost the nation about $316.1 billion per year 
during 2012–2013.4 Reducing the health and economic burden of hypertension and CVD is 
a public health priority.
Substantial knowledge regarding the epidemiology, pharmacologic and non-pharmacologic 
treatments, and genetics of hypertension is available; however, many people with 
hypertension remain undiagnosed or undertreated because health systems cannot efficiently 
identify or treat them, often because of poor access to health care.5 Hypertension control 
remains a major public health challenge.6 To promote effective hypertension prevention and 
control, a better understanding of the economic aspects of hypertension is important. The 
Division for Heart Disease and Stroke Prevention (DHDSP), Centers for Disease Control 
and Prevention, routinely conducts applied research that evaluates program cost, cost of 
illness, and cost effectiveness to address this need. This commentary highlights some 
challenges in quantifying the economic impact, recent research, and future research 
opportunities of hypertension based on the applied research from DHDSP.
DEFINING AND QUANTIFYING ECONOMIC COSTS OF HYPERTENSION
Hypertension is (1) a serious health condition requiring timely and sustained treatment; (2) 
an independent risk factor for many costly chronic diseases including heart disease, stroke, 
and chronic renal disease; and (3) a general health indicator that might be associated with 
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other diseases and conditions unrelated to hypertension. Because of these facts, quantifying 
the economic costs of hypertension is particularly challenging.
Economic costs of hypertension include both direct medical costs and indirect costs such as 
productivity loss. Direct medical costs are the costs incurred for medical products and 
services used to prevent, detect, or treat a disease and its complications.7 These costs include 
the costs of inpatient stays, emergency room visits, physician visits, laboratory and imaging 
tests, home health care, and prescription medications. Although such costs are relatively 
straightforward to estimate because of readily available data and standardized methods, 
differences in study perspectives and scope of the costs, such as “charges” versus 
“payments,” can still present challenges to standardization. Nevertheless, cost estimates are 
easily understood and accepted by most decision makers and other stakeholders. Direct 
medical costs of hypertension include costs for hypertension treatment (i.e., hypertension 
treatment costs) and costs of comorbidities attributable to hypertension (i.e., hypertension-
attributable costs). Hypertension-associated costs, which includes treatment and 
comorbidity-attributable costs, together approximate the economic burden of hypertension.
Limiting the economic cost estimates to hypertension treatment cost alone can substantially 
underestimate the economic burden of hypertension because it ignores the fact that 
hypertension is a major risk factor for many other costly diseases. One study suggested that 
hypertension treatment costs accounted for only 12.1% of hypertension-associated cost.8 
Another study estimated that hypertension treatment costs accounted for about 21% of 
hypertension-associated cost, cardiovascular complications accounted for 27%, and other 
diagnoses for 52%.9 The former study also showed that the composition of the treatment 
cost was substantially different from the composition of hypertension-associated costs 
(Figure 1).8
Indirect costs are incurred from productivity loss because of morbidity and disease-related 
premature mortality.7 Although indirect costs are a significant public health burden, few 
studies on the indirect cost of hypertension exist. One study estimated the indirect cost of 
hypertension to U.S. employers in 2004 at $392 per eligible employee per year, which 
includes presenteeism, work absence, and short-term disability.10 The cost of hypertension 
was found to be highest among ten studied health conditions including heart disease, mental 
disorders, and arthritis. Furthermore, the costs were generally higher than direct medical 
costs. Another study projected the indirect costs of hypertension at $27.2 billion in 2015, 
accounting for about 23% of total costs, with direct medical costs of $91.4 billion.11
People with hypertension-related complications, such as heart disease and stroke, may 
require a substantial amount of informal care, including assistance with activities of daily 
living. This is especially true for older adults. Thus, calculating the economic burden of 
hypertension should also include the costs of informal caregiving. Studies have estimated the 
costs of informal caregiving associated with stroke in the elderly and the cost associated 
with heart failure in people aged >50 years.12,13 Some of these costs could be attributed to 
hypertension.
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RECENT DEVELOPMENT IN RESEARCH ON ECONOMICS OF 
HYPERTENSION
Recent research on the economics of hypertension in the DHDSP has started to address the 
priority areas of hypertension as a secondary diagnosis, informal caregiving, and evaluation 
of program cost and cost effectiveness. Almost all previous cost-of-illness literature has 
relied on data that have only included the costs for hypertension when it was listed as a 
primary diagnosis on medical records.9 Recent research in DHDSP addressed hospitalization 
costs associated with hypertension as a secondary diagnosis.14 Medical costs by primary and 
secondary diagnosis status for heart failure, acute myocardial infarction, ischemic heart 
disease, and stroke have also been investigated. Methods employed by and findings from 
these studies can be used as a foundation for further cost-effectiveness evaluations and 
investigation of comorbidity and aging issues related to many chronic conditions.
Another major contribution to the field is estimating informal caregiving costs for patients 
with heart failure and stroke.12,13 Using a difference-in-difference approach, propensity 
score matching technique, and two-part models, incremental informal caregiving hours and 
costs associated with stroke and heart failure were examined. Some of these costs should be 
attributed to hypertension. These studies provided much needed information for further 
investigating the economic burden associated with hypertension and other chronic 
conditions.
Finally, much needed research in the evaluation of program cost and effectiveness has been 
conducted. A cost analysis of a community health worker program in rural Vermont 
provided a framework for cost evaluations using data from administrative records and 
personal interviews.15 An effectiveness evaluation of full coverage for antihypertension 
drugs in China’s rural communities suggested it was a viable means of enhancing 
medication adherence while reducing total medical costs.16 The cost effectiveness of a 
hypertension control intervention in community health centers in China was also examined.
17
 These research methods and findings could be used to support community-based 
interventions for hypertension control.
FUTURE RESEARCH ON THE ECONOMICS OF HYPERTENSION
The substantial health and economic burden associated with hypertension suggests that 
hypertension prevention is a growing public health priority. Expanding the literature on the 
economics of hypertension can support such a priority. Several specific areas for future 
economic research may be particularly relevant to expand and improve efforts for promoting 
cardiovascular health:
1. The economics of health disparities: Addressing health disparities is a public 
health imperative in the U.S. Researchers have examined health disparity issues 
in chronic conditions including hypertension. However, little research has 
documented the economic aspects of disparities, such as the impact of health 
disparities on medical costs or the cost effectiveness of reducing health 
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disparities. Such economic information can support community- and local-level 
interventions promoting cardiovascular health in disparate population groups.
2. Indirect costs and costs of informal caregiving associated with hypertension: 
More research is needed to better estimate indirect costs. Furthermore, the 
burden of chronic diseases and an aging population may increase the demand for 
formal and informal caregiving, especially for the elderly. Information on 
productivity loss as well as formal and informal caregiving can be used to more 
fully estimate the economic burden and help identify the necessary resources to 
support healthy aging.
3. Economic analyses of comorbidities: Multiple chronic conditions are common 
among people with hypertension. For example, more than 66% of people with 
hypertension have three or more other chronic conditions among Medicare fee-
for-service beneficiaries.18 However, more needs to be done to accurately 
estimate comorbidity costs and avoid counting the same costs for multiple 
conditions (i.e., double counting).
These and other priorities are addressed in research from DHDSP. The articles presented in 
this supplement highlight some of the economic research in these areas. Ongoing and future 
research will continue to advance our knowledge and generate improved methods regarding 
the economics of hypertension. This supplement and other economic research can be used to 
develop, improve, and assess public health interventions for better cardiovascular health.
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Figure 1. Composition of direct medical expenditures of hypertension by service type
Source: Based on findings from “National Estimate of Cost of Illness for Hypertension and 
Non-persistence With Drug Therapy Using the Medical Expenditure Panel Survey” by SE 
Graden, PhD dissertation, Ohio State University, 2003.
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